Phaseline

Targets › CLDN18

CLDN18 (Claudin-18): drug programs, companies and trials

43 programs from 39 companies in 81 trials: 40 Phase 1, 23 Phase 2, 18 Phase 3; Oncology, Gastroenterology; next expected readout Nov 2026.

Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling (By similarity). Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier (By similarity). (UniProt, P56856)

Open in Phaseline: the race on CLDN18, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
LaNova Medicines ZhejiangLM-302
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Locally Advanced or Metastatic GC and GCJ Adenocarcinoma; Malignant Neoplasms of Digestive OrgansNov 2026
AstraZenecaAZD0901
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Gastric CancerNov 2026
Innovent Biologics (Suzhou)IBI343
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; Pancreatic Cancer; CLDN18.2 Positive; Locally Advanced Unresectable or Metastatic Solid Tumors …Dec 2026
Astellaszolbetuximab
Claudin-18 binding agent
CLDN18Phase 3Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Pancreatic Cancer; Pharmacokinetics of Zolbetuximab; Metastatic Pancreatic Adenocarcinoma …Dec 2026
FutureGen Biopharmaceutical (Beijing)M108 monoclonal antibody
anti-CLDN18.2 monoclonal antibody
CLDN18Phase 3Locally Advanced Unresectable or Metastatic Gastric CancerJan 2027
Suzhou Immunofoco BiotechnologyIMC002
anti-CLDN18.2 CAR-T cell therapy
CLDN18Phase 3Gastric AdenocarcinomaMay 2027
Biokin (Shanghai) BiopharmaceuticalBL-M05D1
anti-CLDN18.2 antibody
CLDN18Phase 3Gastric Cancer; Locally Advanced or Metastatic Solid TumorsJun 2027
Shanghai Hengrui PharmaceuticalSHR-A1904
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced Solid Cancer; CLDN18.2-positive Advanced Solid TumorSep 2027
Antengene BiologicsATG-022
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Advanced Gastric or Gastroesophageal Junction Adenocarcinoma; Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced/Metastatic Solid TumorsSep 2027
Shanghai Junshi Bioscience Co., Ltd.JS107 for Injection
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Advanced Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced Solid TumorsOct 2027
AstellasASP2138
Bispecific antibody binding CLDN18.2 on tumor cells and CD3E on T cells
CD3E, CLDN18Phase 3Gastric Adenocarcinoma; Pancreatic Ductal AdenocarcinomaJan 2028
Qilu PharmaceuticalQLS31905
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Gastric or Gastroesophageal Junction Adenocarcinoma; Pancreatic CancerSep 2028
Shanghai Chia Tai Tianqing Pharmaceutical Technology DevelopmentLM-302 Injection
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3AdenocarcinomaOct 2028
NingBo Junyan Hongshi BiosciencesJS107
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Gastric AdenocarcinomaJan 2029
Shanghai Zhongshan HospitalLM-302
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 2Gastric or Gastroesophageal Junction Adenocarcinoma; Biliary Tract CancerDec 2026
I-Mab Biopharma USTJ033721 (givastomig)
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 2Solid TumorDec 2026
First Affiliated Hospital of Ningbo UniversityZebtorizumab
anti-CLDN18 monoclonal antibody
CLDN18Phase 2DLBCLDec 2026
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universitybenmelstobart
Anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 2Unresectable Hepatocellular CarcinomaDec 2026
Ruijin HospitalLM-302
anti-CLDN18.2 antibody
CLDN18Phase 2Gastric Cancer Stage IV; Gastric or Esophagogastric Junction AdenocarcinomaJan 2027
First Affiliated Hospital of Zhejiang UniversityBenmelstobart
Anti-CLDN18.2 monoclonal antibody
CLDN18Phase 2HR+/HER2- Breast CancerApr 2027
The First Affiliated Hospital with Nanjing Medical UniversityZebetuzumab
Claudin-18.2 (CLDN18.2) monoclonal antibody
CLDN18Phase 2Marginal Zone Lymphoma(MZL)Jun 2028
AstellasASP546C (XNW27011)
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 1Pancreatic Adenocarcinoma Metastatic; Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaDec 2026
L & L Bio Co., Ltd., Ningbo, ChinaLB4330
anti-claudin18.2/IL-10 fusion protein
CLDN18, IL10Phase 1Solid TumorDec 2026
CARsgen TherapeuticsCT041 autologous CAR T-cell injection
anti-CLDN18.2 chimeric antigen receptor T-cell
CLDN18Phase 1Pancreatic Cancer; Gastric Cancer; Gastric AdenocarcinomaDec 2026
Hangzhou Sumgen BiotechSG1906
anti-CLDN18.2 antibody or antibody-drug conjugate
CLDN18Phase 1Locally Advanced Unresectable or Metastatic Solid TumorsFeb 2027
Beijing BiotechEB-DT-CAR-NK
Dual-target CLDN18.2/HER2 CAR-NK cells
CLDN18, ERBB2Phase 1Advanced Gastric AdenocarcinomaMar 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineClaudin18.2-targeted CAR-DCs
anti-CLDN18.2 CAR-dendritic cell therapy
CLDN18Phase 1Colorectal NeoplasiaApr 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineClaudin18.2-targeted CAR-T Cells
anti-CLDN18.2 CAR-T cells
CLDN18Phase 1Colorectal NeoplasiaApr 2027
Bolt BiotherapeuticsBDC-4182
Anti-CLDN18.2 monoclonal antibody conjugated to TLR7/8 dual agonist
CLDN18, TLR7, TLR8Phase 1Gastric Cancer Adenocarcinoma MetastaticMay 2027
Zhejiang Cancer HospitalIBI343
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 1Advanced Pancreatic CancerJun 2027
Peking UniversityKD-496
Dual CAR-T cell therapy targeting NKG2D ligands and CLDN18.2
NKG2D, CLDN18Phase 1Gastric CancerJun 2027
Transcenta Therapeutics (Hangzhou)TST001
Anti-CLDN18.2 monoclonal antibody
CLDN18Phase 1Advanced CancerJun 2027
Anova InnovationANO31905
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 1Pancreatic CancerAug 2027
Essen BiotechMesothelin and Claudin 18.2 CAR-T cells
Dual-target CAR-T cells targeting Mesothelin and Claudin 18.2
MSLN, CLDN18Phase 1Pancreatic CancerDec 2027
Legend Biotech USALB1908
anti-CLDN18.2 CAR-T cell therapy
CLDN18Phase 1Gastric CancerDec 2027
Phanes TherapeuticsSpevatamig (PT886)
Bispecific antibody targeting Claudin 18.2 and CD47
CLDN18, CD47Phase 1Gastric or Gastroesophageal Junction AdenocarcinomaDec 2027
Dong-A STDA-3501
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 1Gastric (Stomach) CancerFeb 2028
Shanghai Institute Of Biological ProductsSIBP-A18
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 1Solid Tumor MalignancyMay 2028
Sichuan Kelun-Biotech BiopharmaceuticalSKB315 for injection
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 1Advanced Solid TumorsJun 2028
AstraZenecaAZD5863
T cell-engaging bi-specific antibody targeting CLDN18.2 and CD3
CLDN18, CD3EPhase 1Gastric CancerMar 2029
LigaChem BiosciencesLCB02A
anti-CLDN18.2 antibody-drug conjugate with topoisomerase I inhibitor payload
CLDN18Phase 1Advanced Solid TumorsFeb 2030
Sichuan UniversityDual-targeting CLDN18.2 and PD-L1 CAR-T cells
Dual-targeting CAR-T cells against CLDN18.2 and PD-L1
CLDN18, CD274Phase 1Advanced Solid Tumor–
RemeGenRC118-ADC
Anti-CLDN18.2 antibody-drug conjugate with microtubule inhibitor payload
CLDN18Phase 1Advanced Solid Tumor–

Conditions

Gastric Cancer (11) Pancreatic Cancer (6) Gastric Adenocarcinoma (5) Advanced Solid Tumors (3) Gastric or Gastroesophageal Junction Adenocarcinoma (3) Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer (3) Solid Tumor (3) Advanced Solid Tumor (2) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (2) Advanced Cancer (2) Gastric Cancer Stage IV (2) Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (2)

Modalities

small molecule (17), mixed (15), antibody (5), other (3), protein or peptide (2)

Companies

Astellas (3) AstraZeneca (2) Second Affiliated Hospital, Zhejiang University, School of Medicine (2) RemeGen (1) Shanghai Institute Of Biological Products (1) Peking University (1) Beijing Biotech (1) Sichuan Kelun-Biotech Biopharmaceutical (1) Biokin (Shanghai) Biopharmaceutical (1) Shanghai Zhongshan Hospital (1) Shanghai Junshi Bioscience Co., Ltd. (1) Transcenta Therapeutics (Hangzhou) (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) Shanghai Hengrui Pharmaceutical (1) Ruijin Hospital (1) Innovent Biologics (Suzhou) (1) Antengene Biologics (1) The First Affiliated Hospital with Nanjing Medical University (1) Suzhou Immunofoco Biotechnology (1) Anova Innovation (1)

Related targets

CD3E (2) NKG2D (1) ERBB2 (1) CD274 (1) TLR7 (1) TLR8 (1) MSLN (1) CD47 (1) IL10 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.